Evaluating drug toxicity signals: Is a hierarchical classification of evidence useful or a hindrance?

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 5, 2008, Pages 475-484

  van Staa, Tjeerd P ^a,b   Smeeth, L ^c   Persson, I ^d   Parkinson, J ^a   Leufkens, H G M ^b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diabetes mellitus; Epidemiology; Hypertension; Lipids

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; ROFECOXIB;

ARTICLE; CLINICAL TRIAL; DATA BASE; DRUG SURVEILLANCE PROGRAM; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; METHODOLOGY; OSTEOARTHRITIS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIMULATION;

ADULT; AGED; CAUSALITY; COMPUTER SIMULATION; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SULFONAMIDES; SULFONES;

EID: 44249104468     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1568     Document Type: Article

References (19)

1. Vandenbroucke JP. When are observational studies as credible as randomized trials. Lancet 2004; 363: 1728-1731.
2. Watson DJ, Santanello NC. Observational studies and the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 2006; 15: 199-201.
3. Hadom DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 1996; 49: 749-754.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-1528.
5. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 1247-1255.
6. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
7. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma. prevention. N Engl J Med 2005; 352: 1071-1080.
8. Arellano F. Observational studies and the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 2006; 15: 203-205.
9. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099.
10. van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Q J Med 2005; 98(3): 191-198.
11. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br Med J 2004; 329(7472): 948-957.
12. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 1995; 48: 9-18.
13. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. Br Med J 2004; 329: 31-34.
14. United Nations Environment Programme: Rio Declaration on Environment and Development. Available at bttp://www.unep.org/Documents.multilingual/ Default.asp?DocumentID=78 & ArticleID=1163 [downloaded 13 September 2006].
15. Tunstall-Pedoe H. Relative or attributable risk? Lancet 1981; 2 (8257): 1211-1212.
16. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283-292.
17. European Medicines Agency. URL http://www.emea.eu.int/htms/hotpress/ d6275705.htm
18. Hippesley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 331: 1310-1316.
19. Vandenbroucke JP. Hierarchy of methods. J Clin Epidemiol 1990; 43: 627.